The estimated Net Worth of Sherrington Robin is at least 1.87 百万$ dollars as of 7 March 2024. Mr. Robin owns over 8,641 units of Xenon Pharmaceuticals Inc stock worth over 650,248$ and over the last 10 years he sold XENE stock worth over 662,155$. In addition, he makes 552,842$ as Executive Vice President - Strategy & Innovation at Xenon Pharmaceuticals Inc.
Sign up
Mr. Sherrington XENE stock SEC Form 4 insiders trading
Robin has made over 10 trades of the Xenon Pharmaceuticals Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he exercised 8,641 units of XENE stock worth 85,114$ on 7 March 2024.
The largest trade he's ever made was exercising 72,488 units of Xenon Pharmaceuticals Inc stock on 31 August 2022 worth over 308,074$. On average, Robin trades about 6,317 units every 130 days since 2015. As of 7 March 2024 he still owns at least 16,824 units of Xenon Pharmaceuticals Inc stock.
You can see the complete history of Mr. Robin stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Robin Sherrington biography
Robin Paul Sherrington Ph.D. serves as Executive Vice President - Strategy & Innovation of the Company. Dr. Sherrington previously served as our Executive Vice President, Business & Corporate Development since March 2018, as our Senior Vice President, Business & Corporate Development since February 2012, as our Vice President, Business & Corporate Development from January 2010 to February 2012, and has held various positions in business development and other departments since joining us in March 2001. Prior to joining us, Dr. Sherrington worked at Pfizer, Inc., a global pharmaceutical company, as a neuroscientist from 1999 to 2001. Dr. Sherrington also previously served as Director of Neuroscience, from 1996 to 1999, at the biotechnology companies Axys Pharmaceuticals and Sequana Therapeutics. Prior to 1996 Dr. Sherrington was a post-doctoral fellow at University of Toronto and received his Ph.D. from the University College London, and his B.Sc. with honors from University of Reading.
What is the salary of Robin Sherrington?
As the Executive Vice President - Strategy & Innovation of Xenon Pharmaceuticals Inc, the total compensation of Robin Sherrington at Xenon Pharmaceuticals Inc is 552,842$. There are 5 executives at Xenon Pharmaceuticals Inc getting paid more, with Simon Pimstone having the highest compensation of 2,612,720$.
How old is Robin Sherrington?
Robin Sherrington is 59, he's been the Executive Vice President - Strategy & Innovation of Xenon Pharmaceuticals Inc since 2019. There are 9 older and 12 younger executives at Xenon Pharmaceuticals Inc. The oldest executive at Xenon Pharmaceuticals Inc is Michael Tarnow, 74, who is the Independent Chairman of the Board.
What's Robin Sherrington's mailing address?
Sherrington's mailing address filed with the SEC is 200 - 3650 GILMORE WAY, , BURNABY, A1, V5G 4W8.
Insiders trading at Xenon Pharmaceuticals Inc
Over the last 10 years, insiders at Xenon Pharmaceuticals Inc have traded over 12,977,011$ worth of Xenon Pharmaceuticals Inc stock and bought 724,015 units worth 2,649,316$ . The most active insiders traders include Patrick Machado、Partners L P/Ilbiotechnolog...、Justin D. Gover. On average, Xenon Pharmaceuticals Inc executives and independent directors trade stock every 31 days with the average trade being worth of 818,878$. The most recent stock trade was executed by Elizabeth A. Garofalo on 8 March 2024, trading 3,500 units of XENE stock currently worth 64,960$.
What does Xenon Pharmaceuticals Inc do?
xenon® (nasdaq: xene) is a biopharmaceutical company focused on the development of novel medicines through the application of our proprietary discovery platform, which we refer to as extreme genetics. our product candidates are based on genetic insights derived from our research of families where individuals exhibit severe traits, or phenotypes. we apply our expertise to predict which phenotypes are caused by single-gene defects. by identifying and characterizing the single-gene defects responsible for such severe phenotypes, we gain valuable insights into their function in human biology and their potential as drug targets. given that these targets are often involved in diseases beyond the rare genetic disorders in which they are first identified, we are developing proprietary product candidates to treat both orphan as well as more prevalent diseases.
What does Xenon Pharmaceuticals Inc's logo look like?
Complete history of Mr. Robin stock trades at Xenon Pharmaceuticals Inc
Xenon Pharmaceuticals Inc executives and stock owners
Xenon Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Simon Pimstone,
Chief Executive Officer, Director -
Ian Mortimer,
President, Chief Financial Officer, Corporate Secretary -
Ernesto Aycardi-Fonseca,
Chief Medical Officer -
Dr. Simon N. Pimstone FRCPC, M.B. ChB., M.D., Ph.D.,
Exec. Chairman -
Ian C. Mortimer C.M.A., CPA, CMA, CPA, M.B.A., MBA,
Pres, CEO & Director -
Robin Sherrington,
Executive Vice President - Strategy & Innovation -
James Empfield,
Senior Vice President - Drug Discovery -
Dr. Christopher John Kenney M.D.,
Chief Medical Officer -
Michael Tarnow,
Independent Chairman of the Board -
Dawn Svoronos,
Independent Director -
Gary Patou,
Independent Director -
Frank Holler,
Independent Director -
Michael Hayden,
Independent Director -
Steven Gannon,
Independent Director -
Clarissa Desjardins,
Independent Director -
Mohammad Azab,
Independent Director -
Shelley McCloskey,
Senior Vice President - Human Resources -
Dr. Christopher E. Von Seggern M.B.A., M.P.H., M.P.H. M.B.A, Ph.D.,
Chief Commercial Officer -
Dr. Kenneth Sommerville,
Interim Chief Medical Officer -
Dr. Christopher E. Von Seggern M.B.A., M.P.H., Ph.D., M.P.H. M.B.A,
Chief Commercial Officer -
Sheila M. Grant M.B.A., M.Sc., MBA,
Sr. VP of R&D Operations -
Dr. James R. Empfield,
Exec. VP of Drug Discovery -
Dr. Robin P. Sherrington,
Exec. VP of Strategy & Innovation -
Shelley McCloskey B.A.,
Sr. VP of HR -
Jodi Regts M.B.A., B.A., MBA,
VP of Corp. Affairs & Investor Relations -
Sherry Aulin,
Chief Financial Officer -
Charles J. Cohen,
VP, Biology -
Raymond Winquist,
Head, Translational Research -
Partners L P/Ilbiotechnolog...,
-
Richard H Scheller,
Director -
Christopher John Kenney,
Chief Medical Officer -
Sherry Aulin,
Chief Financial Officer -
Seggern Christopher Von,
Chief Commercial Officer -
Elizabeth A. Garofalo,
-
Patrick Machado,
-
Y. Paul Goldberg,
VP, Clinical Development -
Associates, Llp Mx,
10% owner -
Karen G. Corraini,
Gen. Counsel & Corp. Secretary -
Johnston L Evans,
Director -
Evan A. Stein,
Director -
Gary Bridger,
EVP, Research & Development -
Gillian Cannon,
-
Justin D. Gover,